TABLE 2.
In vitro and in vivo competition assays
| Competing straina | Relevant genotype | Competition indexb
|
nc | |
|---|---|---|---|---|
| In vitro | In vivo | |||
| DSM-V382 | rpoS::pGP704 | 2.0 | 0.20 | 4 |
| DSM-V490 | rpoS::pCVD442 | 1.0 | 0.25 | 8 |
| DSM-V491 | ΔrpoS | 1.2 | 0.21 | 8 |
| DSM-V506 | ΔrpoS (pFY7) | 32 | 1.2 | 8 |
| DSM-V506d | ΔrpoS (pFY7) | 2.0 | 1.7 | 5 |
| DSM-V717 | DSM-V506 cured of pFY7 | 4.2 | 0.12 | 5 |
| DSM-V719 | DSM-V491 reverted | 1.1 | 1.1 | 8 |
| DSM-V720 | DSM-V717 reverted | 2.9 | 0.88 | 5 |
a
All competition assays were between the indicated strain and the isogenic wild-type strain C6709-1 (LacZ+) or AC-V168 (LacZ−) unless otherwise indicated.
b
Calculated by dividing mutant output number by wild-type output number and correcting the quotient for input deviations from 1:1.
c
n, number of animals used per competition experiment. All competitions were conducted in duplicate. Results from a single representative experiment are shown.
d
Competed against DSM-V714 (wild-type carrying pFY7).